NULISA™ leverages a proprietary sequential immunocomplex capture and release mechanism, combined with advanced Next-Generation Sequencing (NGS), to achieve ultra-high sensitivity and scalable multiplexing. NULISAseq panels enable the detection of previously hard-to-measure biomarkers using just 50 μl of plasma or biofluid, offering exceptional sensitivity and specificity. Additionally, the platform supports advanced biomarker discovery with an option for GCP-compliant and GLP-like lab operations, making it ideal for exploratory profiling of clinical trial samples.
NULISAseq™ CNS Disease and Inflammation Panels
NULISAseq Inflammation Panel 250
Profiles inflammatory cytokines and chemokines essential for understanding systemic host responses.
NULISAseq CNS Panel 120
Analyzes key biomarkers like pTau217 for a deeper understanding of the CNS disease.
Resources
Comprehensive Plasma Proteomics by Biognosys
The NULISA affinity-based assays can be combined with Biognosys’ TrueDiscovery® mass spectrometry-based services powered by the P2 Enrichment System to achieve the most comprehensive plasma proteome profiling in your research.
Sample requirements
NULISAseq™ assays require 50 μl of plasma or other biofluid.
Project management
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
